Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Topical Balm Reduces Taxane-Related Nail Damage

      June 12, 2017
      By Lisa Schulmeister, RN, MN, APRN-BC, FAAN
      Article

      A recent study has found that a topical nail bed balm may be effective in preventing and mitigating nail damage, a common adverse effect from taxane chemotherapy.

      A group of researchers in the United Kingdom evaluated the effectiveness of a natural nail balm in preventing or mitigating nail damage, which is a common adverse effect of taxane chemotherapy. They investigated whether a topical nail bed balm containing bioactive, polyphenolic-rich, African salvia officinalis and gaultheria procumbens in a natural base of olea europaea, butyrospermun parkii, cera alba, and theobroma cacao protected the nail beds. This natural nail balm has reported anti-inflammatory, analgesic, antioxidant, and antimicrobial properties.

      Sixty patients (23 male, 37 female) were randomized to apply the natural balm or a scented petroleum balm (placebo control) to the nailbeds 3 times a day during treatment. There were no differences among patient demographics, and type and number of chemotherapy cycles between the 2 groups (all patients received taxanes). At baseline and at the end of chemotherapy treatment, both patients and physicians measured nail health outcomes. Patients completed a Dermatology Life Quality questionnaire and a linear severity scale, and physicians completed a Nail Psoriasis Index (NPSI) and a linear severity scale based on clinical examination and photographs.

      The polyphenolics-rich essential oils and plant-based waxes in the natural nail bed balm significantly reduced chemotherapy-related nail damage and improved nail-related quality of life compared with the plain petroleum-based balm. The researchers recommend additional research, including studying the effect of combining the natural nail bed balm with nail bed cooling. Study findings were presented during a poster session at the 2017 ASCO Annual Meeting and are available here.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with her hair pulled back in front of a dark blue background
      Image of a nurse handing a patient pills
      4 experts in this video
      Related Content

      Photo of 3 people wearing scrubs talking in a hallway

      How to Transition New Nurse Practitioners to Oncology

      Bridget Hoyt
      August 9th 2025
      Article

      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      August 9th 2025
      Podcast

      Anatomical graphic of a person with a highlighted brain tumor

      Rx Road Map: Vorasidenib for the Treatment of Astrocytoma/Oligodendroglioma

      Dalissa Tejera, MSN, APRN, ANP-C
      August 9th 2025
      Article

      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      August 9th 2025
      Podcast

      Image of a bladder

      Intravesical Mitomycin Produces 24-Month Response in Recurrent NMIBC

      Jax DiEugenio
      August 9th 2025
      Article

      Photo of a man in a warehouse with a yellow vest holding his back in pain

      Supporting Male Cancer Survivors in Physical Jobs

      Ariana Pelosci
      August 9th 2025
      Article
      Related Content

      Photo of 3 people wearing scrubs talking in a hallway

      How to Transition New Nurse Practitioners to Oncology

      Bridget Hoyt
      August 9th 2025
      Article

      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      August 9th 2025
      Podcast

      Anatomical graphic of a person with a highlighted brain tumor

      Rx Road Map: Vorasidenib for the Treatment of Astrocytoma/Oligodendroglioma

      Dalissa Tejera, MSN, APRN, ANP-C
      August 9th 2025
      Article

      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      August 9th 2025
      Podcast

      Image of a bladder

      Intravesical Mitomycin Produces 24-Month Response in Recurrent NMIBC

      Jax DiEugenio
      August 9th 2025
      Article

      Photo of a man in a warehouse with a yellow vest holding his back in pain

      Supporting Male Cancer Survivors in Physical Jobs

      Ariana Pelosci
      August 9th 2025
      Article

      Latest Conference Coverage

      PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.